Optimizing PARPi in Ovarian Cancer: Practical Guidance on Current Clinical Management Strategies

Review the latest data and expert guidance on PARP inhibitors to enhance your treatment of ovarian cancer. This comprehensive CME/CE/CPE-certified program features decision support tools, focused commentaries, an expert analysis module, and a downloadable slideset.

Laura Alwan Headshot
Laura Alwan, PharmD, BCOP
person default
Virginia Bayer, BSN, RN, OCN
Robert L. Coleman, MD
Thomas J. Herzog, MD
Ursula Matulonis, MD
Bradley J. Monk, MD, FACS, FACOG
person default
Kathleen Moore, MD

ClinicalThought

Have you fully integrated the PARP inhibitors—olaparib, niraparib, and rucaparib—into your clinical practice in ovarian cancer? In this commentary, I discuss the importance of PARP inhibitors in ovarian cancer treatment and review considerations guiding their use.

Ursula Matulonis, MD Released: May 2, 2019

Are you aware of the latest data on PARP inhibitors in ovarian cancer? In this commentary, I will discuss 3 key studies on olaparib, rucaparib, and niraparib in platinum-sensitive recurrent ovarian cancer that were presented at ASCO 2019.

Robert L. Coleman, MD Released: June 24, 2019

Read this expert commentary to gain practical clinical insights on managing adverse events associated with PARP inhibitors to maximize clinical benefit for patients with ovarian cancer.

Laura Alwan Headshot Laura Alwan, PharmD, BCOP Released: August 27, 2019

Gain expert insights from Kathleen Moore, MD, on key findings from the QUADRA trial that led to FDA label expansion of niraparib in ovarian cancer.

person default Kathleen Moore, MD Released: November 26, 2019

Interactive Decision Support Tool

Use this Interactive Decision Support Tool to see management recommendations in the frontline and second-line settings for advanced-stage ovarian cancer from 5 renowned experts.

Robert L. Coleman, MD Thomas J. Herzog, MD Ursula Matulonis, MD Bradley J. Monk, MD, FACS, FACOG person default Kathleen Moore, MD Released: November 27, 2019

Module

Robert L. Colman, MD; Virginia Bayer, BSN, RN, OCN; and Laura Alwan, PharmD, BCOP, review patient cases and supporting clinical data to provide insights and guidance on the use of PARP inhibitors in ovarian cancer.

Laura Alwan Headshot Laura Alwan, PharmD, BCOP person default Virginia Bayer, BSN, RN, OCN Robert L. Coleman, MD Physicians: maximum of 1.75 AMA PRA Category 1 Credits Registered Nurses: 1.7 Nursing contact hours Pharmacists: 1.75 contact hours (0.175 CEUs) Released: September 25, 2019 Expiration: September 24, 2020

Downloadable Slideset

Download these slides to review expert insights on optimizing the use of PARP inhibitors in ovarian cancer.

Laura Alwan Headshot Laura Alwan, PharmD, BCOP person default Virginia Bayer, BSN, RN, OCN Robert L. Coleman, MD Released: September 25, 2019
Provided by Postgraduate Institute for Medicine
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Supported by independent educational grants from
Clovis Oncology
Tesaro

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?